Skip to main content
Christopher M. Hull
( out of 942 reviews )

Christopher M. Hull, MD

Languages spoken: Spanish, English

Clinical Locations

Primary Location

Midvalley Health Center Dermatology

Dermatology
243 East 6100 South
Murray , UT 84107

University of Utah Hospital

Dermatology, Area E
50 N Medical Dr
Salt Lake City , UT 84132
  • Christopher Hull, MD has specialized expertise in the treatment of autoimmune skin diseases and viral infections of the skin. He is board certified in dermatology. His main clinical focus is general dermatology and medical dermatology including autoimmune blistering diseases.

    Board Certification

    National Board of Medical Examiners

    Patient Rating

    5.0 /5
    ( out of 942 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    Midvalley Health Center

    Dr Hull and his assistants are very good.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hull was wonderful, very understanding. My only comment is that he didn't mention any risks of the treatment.

    UH HOSPITALS AND CLINICS

    Great visit, quick and efficient.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hull is always thorough p, patient and caring.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Hull is always professional and caring.

    UH HOSPITALS AND CLINICS

    I waited in the exam room longer than my actual appointment. I brought up a few concerns and they were looked at, but never really discussed. I was told - "It's a skin tag" but I wasn't told what to do about it, how to fix it, or why I was getting them. I felt rushed and while I understand that the doctor is used to seeing and diagnosing these issues, it is a BIG concern to be and I didn't feel like that was taken into effect.

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hull is a fantastic doctor.

    UH HOSPITALS AND CLINICS

    I've been seen by Dr. Hull For the last several years and I always feel thoroughly assessed, given individual care, and he has a great ear for any concerns i show

    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hull is a fantastic dermatologist and he does a great job explaining his concerns/findings. He's a great doctor!

  • Christopher Hull, MD has specialized expertise in the treatment of autoimmune skin diseases and viral infections of the skin. He is board certified in dermatology. His main clinical focus is general dermatology and medical dermatology including autoimmune blistering diseases.

    Board Certification and Academic Information

    Academic Departments Dermatology -Professor
    Internal Medicine -Adjunct Professor
    Academic Divisions Infectious Diseases
    Board Certification
    National Board of Medical Examiners

    Education history

    Undergraduate Molecular & Cell Biology - University of Colorado - Boulder B.S.
    Undergraduate Universidad de Granada Baccalaureate
    Professional Medical Medicine - University of Washington School of Medicine M.D.
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Residency Dermatology - University of Utah School of Medicine Resident

    Selected Publications

    Journal Article

    1. Hull CM, Levin MJ, Tyring SK, Spruance S (2014). Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis. Antimicrobial agents and chemotherapy, 58(3), 1273-8. (Read full publication)
    2. Hanson N, Hull C, Meyer (2004). Fever and lymphadenopathy in a farmer. Archives of dermatology, 140(12), 1531-6. (Read full publication)
    3. Hull C, Spruance S, Tyring S, Hamed (2006). Single-dose famciclovir for the treatment of herpes labialis. Current medical research and opinion, 22(9), 1699-702. (Read full publication)
    4. Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpo B, Levin MJ, Tyring S, Spruance S (2011). Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. Journal of the American Academy of Dermatology, 64(4), 696.e1-11. (Read full publication)
    5. Zone JJ, Taylor T, Hull C, Schmidt L, Meyer (2007). IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice. The Journal of investigative dermatology, 127(5), 1167-74. (Read full publication)
    6. Topham C, Haynes D, Frigerio A, Hull (2019). Linear amyopathic dermatomyositis with calcinosis cutis responsive to topical sodium thiosulfate. Pediatric dermatology, 36(4), e102-e103. (Read full publication)
    7. Hull CM, Brunton (2010). The role of topical 5% acyclovir and 1% hydrocortisone cream (Xerese¿) in the treatment of recurrent herpes simplex labialis. Postgraduate medicine, 122(5), 1-6. (Read full publication)
    8. Varedi D, Frigerio A, Scaife C, Hull (2019). A novel case of TIF1 gamma autoantibody positive dermatomyositis associated with a non-functional pancreatic neuroendocrine tumor. Dermatology online journal, 25(3), (Read full publication)
    9. Freeman C, Hull C, Sontheimer R, Curtis (2020). Squamous cell carcinoma of the dorsal hands and feet after repeated exposure to ultraviolet nail lamps. Dermatology online journal, 26(3), (Read full publication)
    10. McCaughey C, Machan M, Bennett R, Zone JJ, Hull C (2011). Pimecrolimus 1% cream for oral erosive lichen planus: a 6-week randomized, double-blind, vehicle-controlled study with a 6-week open-label extension to assess efficacy and safety. Journal of the European Academy of Dermatology and Venereology, 25(9), 1061-7. (Read full publication)
    11. Hull C, Larson A, Leachman (2003). Pharmacogenetic candidate genes for melanoma. Pharmacogenomics, 4(6), 753-65. (Read full publication)
    12. Hull C, Spruance (2007). Situational antiviral drug prophylaxis for HSV type 1 recurrences. Herpes, 14(2), 37-40. (Read full publication)
    13. Liddle M, Hull C, Liu C, Powell (2006). Contact urticaria from curcumin. Dermatitis, 17(4), 196-7. (Read full publication)
    14. Amanullah AA, Sahni DR, Sahni VN, Hull CM, Powell DL, Secrest A (2022). Reply to: current treatment modalities in granulomatous cheilitis. International journal of dermatology, (Read full publication)
    15. Sahni D, Hull C, Grant GJ, Florell S, Wada D, Bowen A, Florell (2022). An atypical case of eosinophilic pustular folliculitis with associated secondary follicular mucinosis treated with indomethacin. JAAD case reports,
    16. Kern JA, Amanullah AA, Sahni DR, Mathis JG, Hull CM, Powell DL, Secrest A (2023). Granulomatous cheilitis - is there a role for allergen screening and avoidance?. The Journal of dermatological treatment, 34(1), 2171707. (Read full publication)
    17. Hoshina Y, Wong KH, Galli J, Bacharach R, Klein J, Lebiedz-Odrobina D, Rose JW, Trump B, Hull C, Greenlee JE, Clardy S (2023). Neurologic involvement in seronegative primary Sjögren's syndrome with positive minor salivary gland biopsy: a single-center experience. Frontiers in neurology, 14, 1174116. (Read full publication)
    18. Hopkins ZH, Jimenez A, Taliercio VL, Clarke JT, Hansen CB, Hull CM, Rhoads JLW, Zone JJ, Sahni VN, Kean J, Secrest A (2023). Skin-Related Quality of Life During Autoimmune Bullous Disease Course. JAMA dermatology, 159(11), 1185-1194. (Read full publication)
    19. Marcacci E, Truong A, Wu C, Presson AP, Lewis BKH, Hull C (2023). Improving access to dermatologic care: A retrospective analysis of dermatology rural outreach clinics in Utah and Wyoming compared to an urban academic center. Journal of the American Academy of Dermatology, 90(1), 139-142. (Read full publication)
    20. Herron ED, Snyder AM, Hull CM, LoBello S, Herron M (2024). Fragile hands: targeting nonmelanoma skin cancer on older hands using 595 nm pulsed dye laser. Lasers in medical science, 39(1), 101. (Read full publication)
    21. Tristani-Firouzi B, Herron ED, Hull CM, Herron M (2024). Two Techniques to Avoid Cyst Spray During Excision. Cutis, 114(1), 11-26. (Read full publication)
    22. Sahni V, Teames C, Seifert R, Conley M, deShazo R, Powell D, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins Z (2025). The association between skin allergy testing and oral squamous cell carcinoma in oral lichen planus: a retrospective cohort study. Archives of dermatological research, 317(1), 207. (Read full publication)
    23. Tristani-Firouzi B, Herron ED, Hull CM, Herron M (2024). Scissors and curette supply solution for cutaneous sarcoid papules and nodules. JAAD case reports, 55, 126-127. (Read full publication)
    24. Grant GJ, Sahni DR, Florell AJ, Hull CM, Florell SR, Miles RR, Wada DA, Bowen A (2023). An atypical case of eosinophilic pustular folliculitis with associated secondary follicular mucinosis treated with indomethacin. JAAD case reports, 34, 86-89. (Read full publication)
    25. Stone CJ, Broadbent E, Sahni VN, Gray L, Clarke JT, Hansen CB, Rhoads JLW, Zone JJ, Hull CM, Wu YP, Kean J, Secrest AM, Hopkins Z (2025). Use of the Connor-Davidson Resilience Scale in a Complex Medical Dermatology Clinic: Cross-sectional study evaluating associations between resilience, Health-related Quality of Life and Mental Health. Journal of the American Academy of Dermatology, 93(1), 252-255. (Read full publication)
    26. Noot CH, Hansen AM, Frost Z, Rhoads JLW, Hull CM, Zone JJ, Hopkins Z (2025). Oral lichen planus treated with upadacitinib: A case series. JAAD case reports, 63, 125-127. (Read full publication)
    27. Seifert RM, Teames CR, Sahni V, Noot C, deShazo RA, Powell DL, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins Z (2025). The impact of allergen avoidance on oral lichen planus: A retrospective cohort-based comparison. Journal of the American Academy of Dermatology, (Read full publication)

    Review

    1. Hull CM, Brunton (2010). The Role of Topical 5% Acyclovir and 1% Hydrocortisone Cream (XereseTM) in the Treatment of Recurrent Herpes Simplex Labialis. Postgraduate medicine, 122(5), 1-6.
    2. Nguyen C, Kuceki G, Birdsall M, Sahni DR, Sahni VN, Hull C (2024). Rosacea: Practical Guidance and Challenges for Clinical Management. Clinical, cosmetic and investigational dermatology, 17, 175-190. (Read full publication)
    3. Sahni VN, Yim R, Amanullah A, Sahni D, Powell D, deShazo R, Rhoads JLW, Clarke JT, Hansen CB, Zone JJ, Hull CM, Hopkins Z (2025). An Allergy-Based Approach to Orofacial Granulomatosis: A Narrative Review. Dermatitis, (Read full publication)

    Book Chapter

    1. Hull C, Zone J (2012). Dermatitis herpetiformis and linear IgA bullous dermatosis. Dermatology (Basel, Switzerland),

    Case Report

    1. Jimenez A, Hull C, Zone (2019). Dermatitis herpetiformis resistant to dapsone due to dietary iodide ingestion. JAAD case reports, 5(8), 713-714. (Read full publication)
    2. Abbott J, Kowalski EH, Klein S, DeShazo R, Hull C (2020). Iatrogenic calcinosis cutis secondary to calcium chloride successfully treated with topical sodium thiosulfate. JAAD case reports, 6(3), 181-183. (Read full publication)
    3. Jimenez A, Hull C, Zone (2021). Rituximab therapy for a severe case of pretibial myxedema. JAAD case reports, 10, 28-30. (Read full publication)
    4. Jimenez A, Topham C, Varedi D, Leiferman KM, Hull (2021). Mucosal linear IgA disease with esophageal involvement responsive to ustekinumab. JAAD case reports, 15, 4-6. (Read full publication)

    Letter

    1. Truong A, Laggis CW, Annis TD, Secrest AM, Fino NF, Powell DL, Gardner LJ, Gregory T, Hull CM, Lewis BK (2020). Factors associated with follow-up adherence in patients seen at a referral-based dermatology clinic for the homeless. Journal of the American Academy of Dermatology, 83(2), 629-631. (Read full publication)
    2. Westerdahl S, Hull CM, Clarke JT, Hansen CB, Rhoads JL (2021). A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1¿ antibodies via line immunoassay versus immunoprecipitation. Journal of the American Academy of Dermatology, 84(2), 559-561. (Read full publication)
    3. Ali NS, Sahni VN, Ma BC, Sahni DR, Hull CM, Powell DL, Secrest A (2021). Reply to: low response of granulomatous cheilitis to currently established treatments. Journal of the European Academy of Dermatology and Venereology, 35(12), e930-e931. (Read full publication)
    4. Harris K, Vanderhooft L, Burt L, Vanderhooft S, Hull (2012). Tanning business practices in Salt Lake County, Utah. Journal of the American Academy of Dermatology, 66(3), 513-4. (Read full publication)
    5. Herron ED, Snyder AM, Hull CM, LoBello S, Herron M (2024). Shave Biopsy with Purposeful Electrodesiccation Benefits Small Nonmelanoma Skin Cancer. Journal of cutaneous medicine and surgery, 12034754241308235. (Read full publication)
    6. Seifert RM, Hull CM, deShazo RA, Powell DL, Rhoads JLW, Zone JJ, Hopkins Z (2025). The Impact of Allergen Avoidance in Burning Mouth Syndrome: A Case Series. Dermatitis, (Read full publication)